<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39395053</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Cellular and molecular life sciences : CMLS</Title><ISOAbbreviation>Cell Mol Life Sci</ISOAbbreviation></Journal><ArticleTitle>MERS-CoV-nsp5 expression in human epithelial BEAS 2b cells attenuates type I interferon production by inhibiting IRF3 nuclear translocation.</ArticleTitle><Pagination><StartPage>433</StartPage><MedlinePgn>433</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">433</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00018-024-05458-y</ELocationID><Abstract><AbstractText>Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is an enveloped, positive-sense RNA virus that emerged in 2012, causing sporadic cases and localized outbreaks of severe respiratory illness with high fatality rates. A characteristic feature of the immune response to MERS-CoV infection is low type I IFN induction, despite its importance in viral clearance. The non-structural proteins (nsps) of other coronaviruses have been shown to block IFN production. However, the role of nsp5 from MERS-CoV in IFN induction of human respiratory cells is unclear. In this study, we elucidated the role of MERS-CoV-nsp5, the viral main protease, in modulating the host's antiviral responses in human bronchial epithelial BEAS 2b cells. We found that overexpression of MERS-CoV-nsp5 had a dose-dependent inhibitory effect on IFN-β promoter activation and cytokine production induced by HMW-poly(I:C). It also suppressed IFN-β promoter activation triggered by overexpression of key components in the RIG-I-like receptor (RLR) pathway, including RIG-I, MAVS, IKK-ε and IRF3. Moreover, the overexpression of MERS-CoV-nsp5 did not impair expression or phosphorylation of IRF3, but suppressed the nuclear translocation of IRF3. Further investigation revealed that MERS-CoV-nsp5 specifically interacted with IRF3. Using docking and molecular dynamic (MD) simulations, we also found that amino acids on MERS-CoV-nsp5, IRF3, and KPNA4 may participate in protein-protein interactions. Additionally, we uncovered protein conformations that mask the nuclear localization signal (NLS) regions of IRF3 and KPNA4 when interacting with MERS-CoV-nsp5, suggesting a mechanism by which this viral protein blocks IRF3 nuclear translocation. Of note, the IFN-β expression was restored after administration of protease inhibitors targeting nsp5, indicating this suppression of IFN-β production was dependent on the enzyme activity of nsp5. Collectively, our findings elucidate a mechanism by which MERS-CoV-nsp5 disrupts the host's innate antiviral immunity and thus provides insights into viral pathogenesis.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Viral Immunology Group, Trinity Biomedical Sciences Institute, School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandwal</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Design Group, School of Chemical Sciences, Dublin City University, Glasnevin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Design Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DCU Life Sciences Institute, Dublin City University, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fayne</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Molecular Design Group, School of Chemical Sciences, Dublin City University, Glasnevin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DCU Life Sciences Institute, Dublin City University, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevenson</LastName><ForeName>N J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Viral Immunology Group, Trinity Biomedical Sciences Institute, School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland. STEVENNJ@tcd.ie.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>201908300032</GrantID><Agency>China Scholarship Council</Agency><Country /></Grant><Grant><GrantID>SFI 20/SPP/3685</GrantID><Acronym>SFI_</Acronym><Agency>Science Foundation Ireland</Agency><Country>Ireland</Country></Grant><Grant><GrantID>SFI 19/FFP/6483</GrantID><Acronym>SFI_</Acronym><Agency>Science Foundation Ireland</Agency><Country>Ireland</Country></Grant><Grant><GrantID>GOIPG/2021/954</GrantID><Agency>Irish Research Council</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cell Mol Life Sci</MedlineTA><NlmUniqueID>9705402</NlmUniqueID><ISSNLinking>1420-682X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050838">Interferon Regulatory Factor-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494232">IRF3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>77238-31-4</RegistryNumber><NameOfSubstance UI="D016899">Interferon-beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C106259">KPNA4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>O84C90HH2L</RegistryNumber><NameOfSubstance UI="D011070">Poly I-C</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D028901">alpha Karyopherins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D000071457">DEAD Box Protein 58</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050838" MajorTopicYN="Y">Interferon Regulatory Factor-3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="Y">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004847" MajorTopicYN="Y">Epithelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="Y">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016899" MajorTopicYN="N">Interferon-beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011070" MajorTopicYN="N">Poly I-C</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028901" MajorTopicYN="N">alpha Karyopherins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021581" MajorTopicYN="N">Active Transport, Cell Nucleus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071457" MajorTopicYN="N">DEAD Box Protein 58</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IRF3</Keyword><Keyword MajorTopicYN="N">Interferon</Keyword><Keyword MajorTopicYN="N">KPNA4</Keyword><Keyword MajorTopicYN="N">MERS-CoV</Keyword><Keyword MajorTopicYN="N">Nuclear translocation</Keyword></KeywordList><CoiStatement>The authors have no relevant financial or non-financial interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>21</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>21</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39395053</ArticleId><ArticleId IdType="pmc">PMC11470912</ArticleId><ArticleId IdType="doi">10.1007/s00018-024-05458-y</ArticleId><ArticleId IdType="pii">10.1007/s00018-024-05458-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhang Y, Gargan S, Lu Y, Stevenson NJ (2021) An overview of current knowledge of Deadly CoVs and their interface with innate immunity. Viruses 13(4):560</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8066579</ArticleId><ArticleId IdType="pubmed">33810391</ArticleId></ArticleIdList></Reference><Reference><Citation>Sørensen MD, Sørensen B, GONZALEZ-DOSAL R, Melchjorsen CJ, Weibel J, Wang J, Jun CW, Huanming Y, Kristensen P (2006) Severe Acute Respiratory Syndrome (SARS) Development of Diagnostics and antivirals, vol 1067. Annals of the New York Academy of Sciences, pp 500–505. 1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167626</ArticleId><ArticleId IdType="pubmed">16804033</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. COVID-19 (2023) ; https://covid19.who.int/</Citation></Reference><Reference><Citation>Costanzo M, De Giglio MA, Roviello GN (2022) Anti-coronavirus vaccines: past investigations on SARS-CoV-1 and MERS-CoV, the approved vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV-2 infection. Curr Med Chem 29(1):4–18</Citation><ArticleIdList><ArticleId IdType="pubmed">34355678</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehwinkel JMU, Gack (2020) RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol 20(9):537–551</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094958</ArticleId><ArticleId IdType="pubmed">32203325</ArticleId></ArticleIdList></Reference><Reference><Citation>Platanias LC (2005) Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol 5(5):375–386</Citation><ArticleIdList><ArticleId IdType="pubmed">15864272</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, Dhama K, Yatoo MI, Bonilla-Aldana DK, Rodriguez-Morales AJ (2020) SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview. Infez Med 28(2):174–184</Citation><ArticleIdList><ArticleId IdType="pubmed">32275259</ArticleId></ArticleIdList></Reference><Reference><Citation>CE Comar, CJ Otter, J Pfannenstiel, E Doerger, DM Renner, LH Tan, S Perlman, NA Cohen, AR Fehr, SR Weiss (2022) MERS-CoV endoribonuclease and accessory proteins jointly evade host innate immunity during infection of lung and nasal epithelial cells. Proc Natl Acad Sci 119(21):e2123208119</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9173776</ArticleId><ArticleId IdType="pubmed">35594398</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu DX, Fung TS, Chong KK-L, Shukla A, Hilgenfeld R (2014) Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Res 109:97–109</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7113789</ArticleId><ArticleId IdType="pubmed">24995382</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijay RS, Perlman (2016) Middle East respiratory syndrome and severe acute respiratory syndrome. Curr Opin Virol 16:70–76</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4821769</ArticleId><ArticleId IdType="pubmed">26855039</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C-Y, Liu HM, Chang M-F, Chang SC (2020) Middle East respiratory syndrome coronavirus nucleocapsid protein suppresses type I and type III interferon induction by targeting RIG-I signaling. J Virol 94(13):e00099–e00020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7307178</ArticleId><ArticleId IdType="pubmed">32295922</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui P-Y, Wong L-YR, Fung C-L, Siu K-L, Yeung M-L, Yuen K-S, Chan C-P, Woo PC-Y, Yuen K-Y, Jin D-Y (2016) Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3, vol 5. Emerging microbes &amp; infections, pp 1–9. 1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4855074</ArticleId><ArticleId IdType="pubmed">27094905</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemeyer D, Zillinger T, Muth D, Zielecki F, Horvath G, Suliman T, Barchet W, Weber F, Drosten C, Müller MA (2013) Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J Virol 87(22):12489–12495</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807936</ArticleId><ArticleId IdType="pubmed">24027320</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Ye F, Zhu N, Wang W, Deng Y, Zhao Z, Tan W (2015) Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets. Sci Rep 5(1):1–13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4668369</ArticleId><ArticleId IdType="pubmed">26631542</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong L-YR, Ye Z-W, Lui P-Y, Zheng X, Yuan S, Zhu L, Fung S-Y, Yuen K-S, Siu K-L, Yeung M-L (2020) Middle east respiratory syndrome coronavirus ORF8b accessory protein suppresses type I IFN expression by impeding HSP70-dependent activation of IRF3 kinase IKKε. J Immunol 205(6):1564–1579</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9202338</ArticleId><ArticleId IdType="pubmed">32747502</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Chen X, Bian G, Tu J, Xing Y, Wang Y, Chen Z (2014) Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease. J Gen Virol 95(3):614–626</Citation><ArticleIdList><ArticleId IdType="pubmed">24362959</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao D, Duan L, Huang B, Xiong Y, Zhang G, Huang H (2023) The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING. Sci Signal 16(783):eadd0082</Citation><ArticleIdList><ArticleId IdType="pubmed">37130168</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilgenfeld R (2014) From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 281(18):4085–4096</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7163996</ArticleId><ArticleId IdType="pubmed">25039866</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Hu L, Huang X, Wang C, Zhang Z, Wang Y, Zhang D, Ye W (2020) Potential of coronavirus 3 C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: insights from structures of protease and inhibitors. Int J Antimicrob Agents 56(2):106055</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286838</ArticleId><ArticleId IdType="pubmed">32534187</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung S-Y, Siu K-L, Lin H, Yeung ML, Jin D-Y (2021) SARS-CoV-2 main protease suppresses type I interferon production by preventing nuclear translocation of phosphorylated IRF3. Int J Biol Sci 17(6):1547</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8071772</ArticleId><ArticleId IdType="pubmed">33907518</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Qin C, Rao Y, Ngo C, Feng JJ, Zhao J, Zhang S, Wang T-Y, Carriere J, Savas AC (2021) SARS-CoV-2 Nsp5 demonstrates two distinct mechanisms targeting RIG-I and MAVS to evade the innate immune response. MBio 12(5):e02335–e02321</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8546575</ArticleId><ArticleId IdType="pubmed">34544279</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Ma L, Zhuang Z, Cai S, Zhao Z, Zhou L, Zhang J, Wang P-H, Zhao J, Cui J (2020) Main protease of SARS-CoV-2 serves as a bifunctional molecule in restricting type I interferon antiviral signaling. Signal Transduct Target Therapy 5(1):221</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537955</ArticleId><ArticleId IdType="pubmed">33024073</ArticleId></ArticleIdList></Reference><Reference><Citation>Fani M, Teimoori A, Ghafari S (2020) Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections. Future Virol 15(5):317–323</Citation></Reference><Reference><Citation>Zhu M, Fang T, Li S, Meng K, Guo D (2015) Bipartite nuclear localization signal controls nuclear import and DNA-binding activity of IFN regulatory factor 3. J Immunol 195(1):289–297</Citation><ArticleIdList><ArticleId IdType="pubmed">25994966</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecular Operating Environment (MOE), version 2022.02; Chemical Computing Group Inc.: Montreal, QC, Canada. (2022) 02; https://www.chemcomp.com/en/Products.htm</Citation></Reference><Reference><Citation>De Ioannes P, Escalante CR, Aggarwal AK (2011) Structures of apo IRF-3 and IRF-7 DNA binding domains: effect of loop L1 on DNA binding. Nucleic Acids Res 39(16):7300–7307</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167601</ArticleId><ArticleId IdType="pubmed">21596780</ArticleId></ArticleIdList></Reference><Reference><Citation>Dampalla CS, Miller MJ, Kim Y, Zabiegala A, Nguyen HN, Madden TK, Thurman HA, Machen AJ, Cooper A, Liu L (2023) Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV). Eur J Med Chem 254:115376</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10105399</ArticleId><ArticleId IdType="pubmed">37080108</ArticleId></ArticleIdList></Reference><Reference><Citation>Florio TJ, Lokareddy RK, Yeggoni DP, Sankhala RS, Ott CA, Gillilan RE, Cingolani G (2022) Differential recognition of canonical NF-κB dimers by Importin α3. Nat Commun 13(1):1207</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8904830</ArticleId><ArticleId IdType="pubmed">35260573</ArticleId></ArticleIdList></Reference><Reference><Citation>Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, Shirts MR, Smith JC, Kasson PM, Van Der Spoel D (2013) GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29(7):845–854</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605599</ArticleId><ArticleId IdType="pubmed">23407358</ArticleId></ArticleIdList></Reference><Reference><Citation>Desta IT, Porter KA, Xia B, Kozakov D, Vajda S (2020) Performance and its limits in rigid body protein-protein docking. Structure 28(9):1071–1081e3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484347</ArticleId><ArticleId IdType="pubmed">32649857</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce BG, Wiehe K, Hwang H, Kim B-H, Vreven T, Weng Z (2014) ZDOCK server: interactive docking prediction of protein–protein complexes and symmetric multimers. Bioinformatics 30(12):1771–1773</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4058926</ArticleId><ArticleId IdType="pubmed">24532726</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, Ronneberger O, Willmore L, Ballard AJ, Bambrick J (2024) Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature (630):493–500</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11168924</ArticleId><ArticleId IdType="pubmed">38718835</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo S, Kim T, Iyer VG, Im W (2008) CHARMM-GUI: a web‐based graphical user interface for CHARMM. J Comput Chem 29(11):1859–1865</Citation><ArticleIdList><ArticleId IdType="pubmed">18351591</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner P Center For Coastal and Land-Margin Research, Oregon Graduate Institute of Science and Technology; Beaverton, Ore, USA: 2005. XMGRACE, Version. 5: p. 19</Citation></Reference><Reference><Citation>Liu Y, Qin C, Rao Y, Ngo C, Feng JJ, Zhao J, Zhang S, Wang T-Y, Carriere J, Savas AC (2021) SARS-CoV-2 Nsp5 demonstrates two distinct mechanisms targeting RIG-I and MAVS to evade the innate immune response. MBio 12(5):02335–02321. 10.1128/mbio</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8546575</ArticleId><ArticleId IdType="pubmed">34544279</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Fang L, Wang D, Yang Y, Chen J, Ye X, Foda MF, Xiao S (2017) Porcine deltacoronavirus nsp5 inhibits interferon-β production through the cleavage of NEMO. Virology 502:33–38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111669</ArticleId><ArticleId IdType="pubmed">27984784</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik NG, Lee S-C, Veronese BH, Ma Z, Toth Z (2022) Interaction of HDAC2 with SARS-CoV-2 NSP5 and IRF3 is not required for NSP5-mediated inhibition of type I interferon signaling pathway. Microbiol Spectr 10(5):e02322–e02322</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9603796</ArticleId><ArticleId IdType="pubmed">36173315</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran EJ, King MC, Corbett AH (2014) Macromolecular transport between the nucleus and the cytoplasm: advances in mechanism and emerging links to disease. Biochim et Biophys Acta (BBA)-Molecular Cell Res 1843(11):2784–2795</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161953</ArticleId><ArticleId IdType="pubmed">25116306</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye J, Chen Z, Li Y, Zhao Z, He W, Zohaib A, Song Y, Deng C, Zhang B, Chen H (2017) Japanese encephalitis virus NS5 inhibits type I interferon (IFN) production by blocking the nuclear translocation of IFN regulatory factor 3 and NF-κB. J Virol 91(8). 10.1128/jvi00039 – 17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5375679</ArticleId><ArticleId IdType="pubmed">28179530</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Lu M, Huang B, Lv Y (2018) Porcine circovirus type 2 inhibits interferon-β expression by targeting karyopherin alpha-3 in PK-15 cells. Virology 520:75–82</Citation><ArticleIdList><ArticleId IdType="pubmed">29793076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockbaum GJ, Henes M, Lee JM, Timm J, Nalivaika EA, Thompson PR, Kurt Yilmaz N, Schiffer CA (2021) Pan-3 C protease inhibitor rupintrivir binds SARS-CoV-2 main protease in a unique binding mode. Biochemistry 60(39):2925–2931</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8457326</ArticleId><ArticleId IdType="pubmed">34506130</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonopoulou I, Sapountzaki E, Rova U, Christakopoulos P (2022) Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds. Comput Struct Biotechnol J 20:1306–1344</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8920478</ArticleId><ArticleId IdType="pubmed">35308802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly SM, VanSlyke JK, Musil LS (2007) Regulation of ubiquitin-proteasome system–mediated degradation by Cytosolic Stress. Mol Biol Cell 18(11):4279–4291</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2043544</ArticleId><ArticleId IdType="pubmed">17699585</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayne D (2013) De-peptidising protein–protein interactions–big jobs for small molecules. Drug Discovery Today: Technol 10(4):e467–e474</Citation><ArticleIdList><ArticleId IdType="pubmed">24451636</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A (2021) Highly accurate protein structure prediction with AlphaFold. Nature 596(7873):583–589</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, Jureka AS, Obernier K, Guo JZ, Batra J (2020) Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science 370(6521):eabe9403</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808408</ArticleId><ArticleId IdType="pubmed">33060197</ArticleId></ArticleIdList></Reference><Reference><Citation>Messina F, Giombini E, Agrati C, Vairo F, Ascoli Bartoli T, Al Moghazi S, Piacentini M, Locatelli F, Kobinger G, Maeurer M (2020) COVID-19: viral–host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. J Translational Med 18:1–10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286221</ArticleId><ArticleId IdType="pubmed">32522207</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopfner K-PV, Hornung (2020) Molecular mechanisms and cellular functions of cGAS–STING signalling. Nat Rev Mol Cell Biol 21(9):501–521</Citation><ArticleIdList><ArticleId IdType="pubmed">32424334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Zhou Z, Xiao X, Tian Z, Dong X, Wang C, Li L, Ren L, Lei X, Xiang Z (2021) SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation. Cell Mol Immunol 18(4):945–953</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7907794</ArticleId><ArticleId IdType="pubmed">33637958</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Qiao J, You Q, Zong S, Peng Q, Liu Y, Hu S, Liu W, Li S, Shu X (2021) SARS-CoV-2 Nsp5 activates NF-κB pathway by upregulating SUMOylation of MAVS. Front Immunol 12:750969</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8631293</ArticleId><ArticleId IdType="pubmed">34858407</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Ayyanathan K, Dittmar M, Miller J, Tapescu I, Lee JS, McGrath ME, Xue Y, Vashee S, Schultz DC (2023) SARS-CoV-2 ORF6 protein does not antagonize interferon signaling in respiratory epithelial Calu-3 cells during infection. Mbio, : pp. e01194-23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10470815</ArticleId><ArticleId IdType="pubmed">37377442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, Wang C, Wang Y, Li L, Ren L (2020) Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun 11(1):3810</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392898</ArticleId><ArticleId IdType="pubmed">32733001</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, Jiang H, Zhou J, Lam P, Zhang L (2011) Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques. J Virol 85(8):4025–4030</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3126125</ArticleId><ArticleId IdType="pubmed">21289121</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Tronser T, Peravali R, Reischl M, Levkin PA (2020) High-throughput screening of cell transfection enhancers using miniaturized droplet microarrays. Adv Biosystems 4(3):1900257</Citation><ArticleIdList><ArticleId IdType="pubmed">32293151</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillyer P, Shepard R, Uehling M, Krenz M, Sheikh F, Thayer KR, Huang L, Yan L, Panda D, Luongo C (2018) Differential responses by human respiratory epithelial cell lines to respiratory syncytial virus reflect distinct patterns of infection control. J Virol 92(15). 10.1128/jvi.02202-17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6052282</ArticleId><ArticleId IdType="pubmed">29769339</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Xie J, Zhang X, Chen L, Bi Y, Li X, Idris A, Feng R (2022) DDX56 antagonizes IFN-β production to enhance EMCV replication by inhibiting IRF3 nuclear translocation. Vet Microbiol 264:109304</Citation><ArticleIdList><ArticleId IdType="pubmed">34922148</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamrashdi MAG, Brady (2022) Regulation of IRF3 activation in human antiviral signaling pathways. Biochem Pharmacol 200:115026</Citation><ArticleIdList><ArticleId IdType="pubmed">35367198</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiscott J, Nguyen T, Arguello M, Nakhaei P, Paz S (2006) Manipulation of the nuclear factor-κB pathway and the innate immune response by viruses. Oncogene 25(51):6844–6867</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7100320</ArticleId><ArticleId IdType="pubmed">17072332</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottipati K, Holthauzen LMF, Ruggli N, Choi KH (2016) Pestivirus Npro directly interacts with interferon regulatory factor 3 monomer and dimer. J Virol 90(17):7740–7747</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4988160</ArticleId><ArticleId IdType="pubmed">27334592</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Z, Zhang M-X, Tang Z, Zhang Q, Ye J, Xiong T-C, Zhang Z-D, Zhong B (2020) USP22 promotes IRF3 nuclear translocation and antiviral responses by deubiquitinating the importin protein KPNA2. J Exp Med, 217(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7201923</ArticleId><ArticleId IdType="pubmed">32130408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, Zhang X, Tarbet B, Marty MT, Chen Y (2020) Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res 30(8):678–692</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7294525</ArticleId><ArticleId IdType="pubmed">32541865</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng CS, Stobart CC, Luo H (2021) Innate immune evasion mediated by picornaviral 3 C protease: possible lessons for coronaviral 3 C-like protease? Rev Med Virol 31(5):1–22</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883238</ArticleId><ArticleId IdType="pubmed">33624382</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Ma C, Szeto T, Hurst B, Tarbet B, Wang J (2021) Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses. ACS Infect Dis 7(3):586–597</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7944397</ArticleId><ArticleId IdType="pubmed">33645977</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Fang L, Shi Y, Zhang H, Gao L, Peng G, Chen H, Li K, Xiao S (2016) Porcine epidemic diarrhea virus 3 C-like protease regulates its interferon antagonism by cleaving NEMO. J Virol 90(4):2090–2101</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4733996</ArticleId><ArticleId IdType="pubmed">26656704</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters JR (2002) HeLa cells 50 years on: the good, the bad and the ugly. Nat Rev Cancer 2(4):315–319</Citation><ArticleIdList><ArticleId IdType="pubmed">12001993</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma SV, Haber DA, Settleman J (2010) Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 10(4):241–253</Citation><ArticleIdList><ArticleId IdType="pubmed">20300105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kube D, Sontich U, Fletcher D, Davis PB (2001) Proinflammatory cytokine responses to P. Aeruginosa infection in human airway epithelial cell lines. Am J Physiology-Lung Cell Mol Physiol 280(3):L493–L502</Citation><ArticleIdList><ArticleId IdType="pubmed">11159033</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M, Li Q, Wang R (2016) Current experimental methods for characterizing protein–protein interactions. ChemMedChem 11(8):738–756</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7162211</ArticleId><ArticleId IdType="pubmed">26864455</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnoldo A, Kittanakom S, Heisler LE, Mak AB, Shukalyuk AI, Torti D, Moffat J, Giaever G, Nislow C (2014) A genome scale overexpression screen to reveal drug activity in human cells. Genome Med 6:1–16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4062067</ArticleId><ArticleId IdType="pubmed">24944581</ArticleId></ArticleIdList></Reference><Reference><Citation>Skariyachan S, Challapilli SB, Packirisamy S, Kumargowda ST, Sridhar VS (2019) Recent aspects on the pathogenesis mechanism, animal models and novel therapeutic interventions for Middle East respiratory syndrome coronavirus infections. Front Microbiol 10:569</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448012</ArticleId><ArticleId IdType="pubmed">30984127</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>